Krittayaphong 2003.
Methods | Randomised controlled trial. | |
Participants | Included patients with: (1) 15‐75 years old; (2) symptomatic paroxysmal or persistent AF for more than 6 months; (3) refractory to at least 1 antiarrhythmic medication including class IA or IC agents, digitalis, beta‐blocker, or calcium channel blocker; (4) never been given amiodarone. 30 patients were enrolled. 15 patients were assigned to PVI and linear ablation of right atrium group, and 15 to medicine group. Age: 48.6+/‐15.4 years in amiodarone group, and 55.3+/‐10.5 years in RFCA group. % of male: 8/15 (53.3%) in amiodarone group, and 11/15 (73.3%) in RFCA group. Follow‐up: 12 months. Location: Bangkok, Thailand. |
|
Interventions | Catheter ablation group: Pulmonary vein isolation and linear ablation of right atrium. Medicine group: amiodarone (1200mg per day for 1 week, 600mg per day for another 2 weeks, and the maintenance dose was 200mg per day). |
|
Outcomes | Effects of treatment on symptoms and quality of life, effects of treatment on cardiac rhythm, adverse effects. | |
Notes | ||
Risk of bias | ||
Bias | Authors' judgement | Support for judgement |
Random sequence generation (selection bias) | Unclear risk | Insufficient detail was provided. |
Allocation concealment (selection bias) | Unclear risk | B‐Unclear. The authors did not depict allocation concealment method. |
Blinding | High risk | Blinding was not reported. |
Incomplete outcome data addressed | High risk | There were no patients withdrawn or lost to follow up. |
Adequate sequence generation | Unclear risk | It was not addressed. |